VEGFA and renal cell carcinoma: A retrospective study that consisted of 43 patients with metastatic sarcomatoid RCC who received VEGF-targeted therapy showed that progression free survival (PFS) was much longer in patients who had non-sarcomatoid RCC compared to those with sarcomatoid RCC (16.3 months vs 6.2 months; p< 0.001) [3].